Jensen will Oversee Company's New Drug Application (NDA) Process for Prana
DENVER, CO / ACCESSWIRE / September 13, 2017 / United Cannabis Corporation (OTCQB: CNAB) (the "Company" or "United Cannabis") today announced that Murray Jensen has joined the Company's Medical Advisory Board and is tasked with overseeing the Company's Investigational New Drug (IND) application process with the Food and Drug Administration (FDA).
Mr. Jensen brings extensive expertise in drug development, with over 25 years' experience in research for pharmaceutical, medical device and natural health products in a wide variety of therapeutic areas. He has held numerous senior clinical research positions at pharmaceutical and biotechnology companies, and for the past 15 years has served as Managing Director of ethica CRO Inc. where he is responsible for Business Operations and Clinical and Scientific Affairs.
Commenting on the appointment, Mr. Jensen stated, "United Cannabis has developed a noteworthy portfolio of phyto-therapeutic products and I am very impressed with the results documented in their preliminary testing, including their cannabis-centric Prana line of medications. I look forward to working with the Company to establish and implement the research protocols and IND applications that will make these products available to a broader audience."
Earnest Blackmon, Chief Executive Officer of United Cannabis, added, "Murray is a great addition to our Medical Board. His expertise in the development and implementation of successful clinical trials, as well as his experience in working with the FDA will be invaluable as we begin testing our products in the clinic. Now that we have secured a patent for the Prana product line, FDA approval is our first priority, and we are excited to begin this step with Murray at the helm."
Mr. Jensen earned a Master's Degree of Science in Medical Science, Neuropathology, and served on the faculty at the University of Calgary, Alberta, before embarking on a successful career in drug development with companies in the global pharmaceutical, biotechnology and CRO industries. He has also published numerous manuscripts and peer-reviewed articles in neurology, cardiology, dermatology, and clinical trial methodology.
About United Cannabis Corporation
The Company's Prana Bio Medicinal products provide patients a way to mix/match cannabinoids for therapeutic purpose. These products, licensed to regulated marijuana dispensaries, are broken into 5 categories that are available in capsules, sublinguals, and topical delivery methods. The Company uses a patent-pending infusion process utilizing select fatty acids, lipids, and specific combination of cannabis-derived terpenes to increase bioavailability.
For further information, please visit www.unitedcannabis.us.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors, created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
SOURCE: United Cannabis Corporation